In this issue:
Revised “iRR6” model enhances risk stratification in intermediate-1 risk patients
Post-transplant cyclophosphamide GvHD prophylaxis delays engraftment
Pre-transplant splenic irradiation is safe and effective for splenomegaly
Early ruxolitinib initiation is beneficial regardless of fibrosis grade
Comparable outcomes with alternative vs HLA-matched donors
Clinical practice recommendations for myelofibrosis management in the Asia-Pacific region
ADORE: promising preliminary efficacy for ruxolitinib + siremadlin
Socio-demographic determinants of myelofibrosis outcomes
Please login below to download this issue (PDF)